MedTrace Logo

Procalcitonin in Cirrhotic Patients at High Risk for Sepsis

NCT01578226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2012-04-16

No results posted yet for this study

Summary

Infections are frequent life-threatening events in patients with cirrhosis, occurring at least in 35% of hospitalized patients and accounting for 20% of inpatients death. Among cirrhotics, ascitic patients have the highest risk of death for sepsis. At the admission, no clear-cut clinical and biochemical features are helpful in diagnosing and prognostically stratifying those patients with sepsis. Procalcitonin (PCT)is a breakthrough marker presenting high sensibility and specificity in diagnosing bacterial infections in different clinical settings. The purpose of this study is to evaluate PCT as a diagnostic and prognostic tool for sepsis in hospitalized cirrhotic patients with ascitic decompensation.

Conditions

Sponsors & Collaborators

  • Prof. Facchinetti Fabio

    lead OTHER

Principal Investigators

  • Filippo Schepis, MD · University of Modena and Reggio Emilia

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-09-30
Completion
2011-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578226 on ClinicalTrials.gov